All In Biotech

NDA 014879 · Hikma

Dopram

Doxapram Hydrochloride · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Mar 29, 2006 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1965

Jun 23, 1965

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

1 Phase 3, 2 recruiting

FAERS reports

22

21 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2025.

INDICATIONS & USAGE Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 23, 1965 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • DOPRAM · DOXAPRAM HYDROCHLORIDE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxapram" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • depressed level of consciousness5
  • atrial fibrillation4
  • respiratory failure4
  • electrocardiogram qt prolonged3
  • hepatic failure3
  • hepatitis fulminant3
  • bradycardia2
  • cardiac failure2
  • delayed recovery from anaesthesia2
  • ejection fraction decreased2
  • hypokalaemia2
  • hypoxia2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20063
20082
20093
20102
20111
20121
20141
20151
20162
20202
20231

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 103 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.